Many of us may have taken ibuprofen, sometimes two pills at once, especially when we are struggling with menstrual cramps. Well, as good these pills may be in treating the pain, they are not recommended for your health, especially if you are someone who consumes it on a daily basis or frequently. Gastroenterologist Trisha Pasricha, MD, writes in The Washington Post about why should you avoid taking nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, naproxen and aspirin.

What happens when you consume pain killers?

She writes that NSAIDs are great in treating short term pain. They comprise of a group of drugs that inhibit the production of prostaglandins, which serve as a variety of purposes in the body. Some of which also includes contracting the uterus during menses and regulating blood flow in our vessels.

While one to two doses every now and then is okay, following a regular dosage routine, which could range from several times a month, or twice in an hour or so could lead to health risk. NSAIDs are well known to increase intestinal permeability. This means, these painkillers could damage the lining of your gut.

A 2018 review by Ingvar Bjarnason et. al., also writes about how NSAIDs can reduce the blood flow in the tiny vessels that feeds our guts. It can also disrupt the intestinal cells forming a barrier between the outside world and your insides.

What can be done?

While people with conditions like migraines, chronic back pain or bad period cramps can find NSAIDs to be helpful. It is always advisable to have a chat with your physicians to explore NSAID alternatives.

Pasricha suggests acetaminophen.

However, if someone is in dire need of NSAID, her tip is to take the pill right at the start of your symptoms. She says that the drug can do a far better job at stopping things at the source than chasing after all prostaglandins.

Why is it a concern?

NSAIDs are available as over the counter drug, which means people do not need a prescription for it and can make medical decision about them without the guidance of a physician.

A 2018 study published in the Official Journal of the International Society for Pharmacoepidemiology by David W Kaufman, et.al., found that 15% of adult ibuprofen users in the US have exceeded the maximum recommended daily dose. The study also mentions that more than a third of ibuprofen users were taking other NSAIDs, like aspirin and naproxen, while consuming ibuprofen at the same time. Out of these, 61% did not realise that they were using NSAIDs.

Pasricha talks about how it ruptures the gut wall, as she herself has rushed to the hospital in the middle of the night "far more times than" she can count "to perform an emergency endoscopy on someone who was bleeding profusely from an ulcer caused by NSAID".

Another 2009 study published in the American Journal of Gastroenterology states that as many as 1 in 4 chronic NSAID users will get an ulcer and about 4% will bleed or rupture through the gut wall.

An older study from 2005 titled A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy, found that as 75 percent of people regularly using NSAIDs develop low-grade inflammation in their small bowels. NSAIDs can also lead to development of fatty liver disease. This happens because your gut lining becomes more permeable, more toxins and bacteria from the outside world enters your liver and leads to inflammation.

A 2011 study titled Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials, states that as many as 6% of people taking NSAIDs regularly have found their blood count dropping within a few months of starting the medicines, this suggests that this is due to the small, slow amount of bleeding in the gut overtime.

When patients first hear the term "bone marrow transplant," they often picture a complex surgery involving the bones or spine. This is perhaps the most persistent misconception surrounding one of modern medicine's most remarkable achievements.

Unlike other organ transplants (kidney/ heart/ liver, etc), a bone marrow transplant is not a surgery at all! It is administered much like a blood transfusion, through a simple intravenous line. Yet this deceptively simple procedure can rebuild an entire blood-forming and immune system from scratch, offering a genuine cure for blood cancers and other serious blood disorders.

Bone marrow is the body's blood factory, producing the red cells that carry oxygen, the white cells that fight infection, and the platelets that prevent bleeding. At its heart lie blood-forming stem cells or the "parent cells" capable of generating every blood cell the body will ever need.

In leukemia and related cancers, these stem cells turn rogue, crowding out healthy ones. In several inherited disorders, the marrow simply fails to manufacture healthy cells at all. A transplant addresses the problem at its root, replacing defective stem cells with healthy ones.

I often explain this to patients using the language of farming. Before sowing fresh seed, a farmer clears the field of weeds. Similarly, before healthy stem cells can be transplanted, doctors must prepare the marrow through chemotherapy and, in select cases, radiation, a stage called conditioning. Once this was punishingly intensive, limiting transplants to the young and fit. Today, reduced-intensity regimens, which are carefully tailored to suit even the old or frail patients, have extended this option to older adults and those with other health conditions.

The transplant itself is almost anticlimactic in its simplicity: stem cells are infused through an IV, with no incision or operating theatre required. These cells possess a natural ability doctors call "homing": they find their own way into the bone marrow and settle there. Over two to four weeks, they begin producing healthy blood, a process called engraftment.

For decades, the greatest obstacle to transplantation was finding a matched donor. Traditionally, only a fully matched sibling would do, leaving many patients, particularly in a genetically diverse country like India, without options. That has changed decisively. Half-matched family transplants and unrelated donors identified through registries now succeed at rates that rival matched-sibling transplants. Nearly every patient today has a realistic path to a suitable donor.

Technology is reshaping this field further. Gene therapy is opening a new chapter for disorders such as sickle cell disease and thalassemia, correcting a patient's own stem cells in the laboratory rather than relying on a donor, though such therapies remain costly and available only in select countries for now.

Recovery, however, is a marathon, not a sprint. It can take months as the immune system rebuilds, requiring vigilant monitoring for infection and for graft-versus-host disease, in which transplanted immune cells attack the patient's own tissues. Advances in immunosuppressive and targeted therapies have greatly improved our ability to manage this complication, allowing most survivors to gradually return to work, education and family life.

A blood cancer diagnosis remains frightening, but treatment has advanced tremendously in two decades. Bone marrow transplantation is no longer experimental or exceptionally hazardous: it is established, evidence-based, and growing safer and more accessible across India.

Its truest achievement is not simply extending life, but restoring it: another birthday, another child watched growing up, another future reclaimed. For these patients, a transplant is quite literally a chance to begin again.

(Dr. Narendra Agrawal, Hematologist and Bone Marrow Transplant Physician and Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute & Research Centre.)

A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.

The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.

What Is the 6-in-1 Vaccine?

The hexavalent vaccine protects children against six diseases with a single injection:

• Diphtheria
• Tetanus
• Pertussis (whooping cough)
• Hepatitis B
• Hemophilus influenzae type b (Hib)
• Polio

Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.

Key Findings

Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526

Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.

The study estimated that:

• A 50% reduction in the vaccine price would allow operational savings to outweigh the additional vaccine procurement costs under the primary immunization schedule.
• Lower vaccine prices could also make broader implementation, including booster doses, economically beneficial.

The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.

Potential Benefits of the 6-in-1 Vaccine

According to the study, introducing the hexavalent vaccine could:

• Reduce the number of injections for infants.
• Make immunization visits more convenient for children and caregivers.
• Lower cold-chain storage requirements
• Reduce the use of syringes and other vaccination supplies.
• Save time for Auxiliary Nurse Midwives (ANMs) during vaccine administration and record-keeping
• Reduce the workload of cold-chain handlers and vaccine managers.
• Save time for parents and caregivers during vaccination visits.

India's Current Immunization Program

Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients

India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.

The program protects children against 12 vaccine-preventable diseases, including:

• Diphtheria
• Pertussis
• Tetanus
• Polio
• Measles
• Rubella
• Tuberculosis
• Hepatitis B
• Hib-related meningitis and pneumonia
• Rotavirus diarrhea
• Pneumococcal pneumonia
• Japanese encephalitis (in endemic districts)

What the Study Evaluated

A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:

• Replacing the current pentavalent vaccine and fractional inactivated polio vaccine (fIPV) with the hexavalent vaccine during the primary immunization schedule.
• Replacing both the primary schedule and the DTP booster dose with the hexavalent vaccine.

The analysis considered costs from both government and household perspectives, including:

• Vaccine procurement
• Syringes and vaccination supplies
• Cold-chain logistics
• Healthcare worker time
• Caregiver time

The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:

• Lower vaccine delivery costs
• Reduced syringe use
• Lower cold-chain requirements
• Time savings for healthcare workers involved in procurement, storage and vaccine administration

The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.

"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.

Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.

Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.

The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.

"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.

Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.

What Does the Trial Aim to Find?

Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study

The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.

Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.

Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.

Oral Semaglutide May Help Reduce Heavy Drinking

Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.

The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.

The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.

Read More: GLP-1 Microdosing: People Are Experimenting With Weight Loss Drugs & What Do Experts Have To Say About It?

While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.

Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.

"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.